Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. - Wikidata - awgldk - TriplyDB

Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

http://www.wikidata.org/entity/Q37963823

about

Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.Generation and characterization of a human nanobody against VEGFR-2.Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma.Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.A phase II study of axitinib in advanced neuroendocrine tumors.Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.Key pathways and genes controlling the development and progression of clear cell renal cell carcinoma (ccRCC) based on gene set enrichment analysis.Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).The many facets of PEDF in drug discovery and disease: a diamond in the rough or split personality disorder?Can a treatment be licenced on the basis of post-treatment predictive biomarkers?Current adjuvant therapeutic approaches for pancreatic cancer.The changing landscape of phase I trials in oncology.Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions.Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma.Safety of available treatment options for renal cell carcinoma.Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.Adverse events of monoclonal antibodies used for cancer therapy.Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer?Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma.Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.

P2860

Q26750719-ACD669E0-6DE9-403F-A924-FCCD13D0DB8C Q26751274-C0C72033-EBAB-424D-B026-E5EEB59EF03D Q26998790-A185F319-69D0-484A-A9E9-A8D801F0922D Q28067583-8C8E39BD-AE62-46DE-85EA-11B442FAB711 Q28539534-EF472413-C7B1-4E78-B0D8-1D25BAFEC46B Q28545130-0A21479D-19B0-4D4A-990A-44A47B5BE30E Q33422376-788ABCE1-2460-4359-A7CD-7059E6AC5559 Q33426958-5CADAEE8-6B00-4121-B071-9515DA76CBBF Q33770680-61DE4F8D-29A3-4EE9-B0CB-F50D90B568AC Q34365135-369B336A-6384-460A-B7D4-DEBA18EDF320 Q34523277-55D96056-D90F-4452-B6D7-13DCFB5277B9 Q35739362-5330E660-AF3D-44AC-B5F0-235B0FD72689 Q36243104-01663231-674C-40F7-BF5A-C159CE723BA3 Q37131421-13DA43E6-1F1E-47CD-8241-56C040C1E691 Q37438970-718F39BF-B6FE-4E5D-8F3B-A0AB2CF3CA4A Q37589551-637E21E2-46E1-4230-A3EA-8332AFE0EEF7 Q37621799-FCADBF90-B4C2-4B9F-98DC-9B5F34D1100F Q37639475-4FF99F38-7626-48C2-B1A2-812A0DF24A96 Q37670436-16B7E8B8-BDEC-446A-8BF3-10BBB6C124D3 Q38101883-1AFF42C5-85F6-4236-B3B5-600A657EE346 Q38103913-DC3851F8-15EC-4D17-ACC4-9B9B94C0C53B Q38210285-79FC82E3-11F4-4E14-ABCF-FBD794C3F745 Q38321245-6A50D297-5EB5-4F06-909E-74CDB805BE52 Q38629203-244EA05B-4168-4DB4-978F-EEA32F8C9DAB Q38633532-E86E74CE-0529-4CD6-B5E5-3C80A526126A Q38647604-D7F6D0EF-39C2-4882-9399-85F347D0337D Q38823987-DB2444B4-93F2-4201-BC81-EF810111BC2A Q38824719-D904A791-DCCD-423F-AF4D-D047532E85A2 Q38930166-01205E65-9D09-43F7-BE9E-A4E8983FE2D6 Q39473582-710AE602-3199-4FD4-A7AB-A2B07CFE2A38 Q40812370-0E5818C0-3CA2-4119-B6EE-CC198D84A302 Q42336244-A1BAC54C-DDE2-4C50-AC36-AF7D46DEB9E3 Q42581249-2F04F606-46F9-4841-926F-596BEA45FBBB Q47123004-32F7298A-E3C2-42E2-858E-51B74924053F Q47888326-0FC0F3F8-4265-41E0-A995-5DB8ED434272 Q55069897-DECD20A7-9E81-4D0C-8E87-9015727B12B0

P2860

Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

http://www.wikidata.org/entity/Q37963823

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.

@en

Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.

@nl

type

label

Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.

@en

Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.

@nl

prefLabel

Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.

@en

Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.

@nl

P1433

Q37963823-B6E846FC-72A1-4A0A-8BAB-FB7E5AE8E85A

P1476

Q37963823-F937D0F8-A6FC-45AF-A200-F5048260EE18

P2093

Q37963823-62E3F837-FD9A-428B-AC25-D73B9EE8D783

Q37963823-8CD24F2C-1E6A-418F-9FF9-67F597162BCC

Q37963823-A62B7A14-7F94-4830-85D5-01EFF057FDD4

P2860

Q37963823-01FD2B73-4CEB-466E-9CA5-0BF6A0759C76

Q37963823-1604E3B8-D823-4E83-BB61-9AE74823F4D7

Q37963823-19BF0B0F-B7DF-4A3F-A5F7-0C2074C25AE4

Q37963823-1A1133FB-C838-462C-890D-DBE9D5133E13

Q37963823-1AB1D92A-DE26-4C95-87DD-455AE9972D3F

Q37963823-1D2E9D5D-D72A-4432-8D06-D95763C43FC2

Q37963823-271BAF33-2F5F-4FEF-BD74-29BFD5C658C5

Q37963823-2C541453-20DB-411B-940E-BF5CECA54EB1

Q37963823-38762E00-BED3-4E00-9E5E-878767A94AEE

Q37963823-38CB6CF1-4EFF-49BF-A119-F0B6519C7040

P304

Q37963823-110DA975-5DB3-4F52-80B9-7AECA564CEBB

P31

Q37963823-9732F3B7-88BD-4253-AA5C-66017399528D

P356

Q37963823-2B931480-88A1-4069-AA86-30EC443FC3DA

P433

Q37963823-9BF4724A-D3C9-4B3E-BF22-42BDA97E4D7B

P478

Q37963823-883C2701-3DA0-443A-B886-7D9CF6176655

P50

Q37963823-96F8FB24-858C-48B1-8B12-60AE857251B2

P577

Q37963823-B8BC7352-C01F-4D6D-8A84-F2972ACC241C

P5875

Q37963823-FD1A6024-E341-4099-907E-211F1A6229E8

P698

Q37963823-4560F5EF-A56A-4F08-A027-982CC33DC849

P921

Q37963823-897C2C01-D5C0-4080-BADE-CDCF4032E39C

P932

Q37963823-2307D754-0019-4447-BE39-BD762543A23B

P356

THEONCOLOGIST.2011-0163

P1433

P1476

Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.

@en

P2093

Irene Braña

http://www.w3.org/2001/XMLSchema#string

Jordi Rodon

http://www.w3.org/2001/XMLSchema#string

Rodrigo Dienstmann

http://www.w3.org/2001/XMLSchema#string

P2860

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

P304

1729-1740

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2011-0163

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Josep Tabernero

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51847409

http://www.w3.org/2001/XMLSchema#string

P698

22135123

http://www.w3.org/2001/XMLSchema#string

P921

P932

3248772

http://www.w3.org/2001/XMLSchema#string